Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?

2016 ◽  
Vol 18 (5) ◽  
Author(s):  
Kimberly Janet Legault ◽  
Amaia Ugarte ◽  
Mark Andrew Crowther ◽  
Guillermo Ruiz-Irastorza
Keyword(s):  
General Population ◽  
Antiphospholipid Syndrome ◽  
Recurrent Thrombosis

Livedoid vasculopathy and recurrent thrombosis in a patient with lupus: seronegative antiphospholipid syndrome?

Lupus ◽  
2010 ◽  
Vol 19 (11) ◽  
pp. 1340-1343 ◽  
Author(s):  
B. Sopeña ◽  
MT Pérez-Rodríguez ◽  
A. Rivera ◽  
JA Ortiz-Rey ◽  
J. Lamas ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Recurrent Thrombosis ◽  
Livedoid Vasculopathy

scholarly journals Prevention of Recurrent Thrombosis in the Antiphospholipid Syndrome

Lupus ◽  
1994 ◽  
Vol 3 (2) ◽  
pp. 73-74 ◽  
Author(s):  
Jean-Charles Piette
Keyword(s):  
Antiphospholipid Syndrome ◽  
Recurrent Thrombosis

Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response

2015 ◽  
Vol 136 (6) ◽  
pp. 1174-1178 ◽  
Author(s):  
Sabrina da Silva Saraiva ◽  
Isadora Fernandes Custódio ◽  
Bruna de Moraes Mazetto ◽  
Marina Pereira Collela ◽  
Erich Vinícius de Paula ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Inflammatory Response ◽  
Cardiovascular Risk Factors ◽  
Antiphospholipid Syndrome ◽  
Recurrent Thrombosis

The Epidemiology of Cancer-Associated Venous Thromboembolism: An Update

2019 ◽  
Vol 45 (04) ◽  
pp. 321-325 ◽  
Author(s):  
Anjlee Mahajan ◽  
Ann Brunson ◽  
Richard White ◽  
Ted Wun
Keyword(s):  
Venous Thromboembolism ◽  
General Population ◽  
Cancer Patients ◽  
Race And Ethnicity ◽  
Cancer Type ◽  
Recurrent Thrombosis ◽  
Factors Associated ◽  
Cancer Associated Thrombosis

AbstractThe incidence of venous thromboembolism (VTE) is known to be higher in patients with malignancy as compared with the general population. It is important to understand and review the epidemiology of VTE in cancer patients because it has implications regarding treatment and prognosis. Multiple studies have shown that cancer patients who develop VTE are at higher risk for mortality. This article will focus on an update regarding the epidemiology of cancer-associated thrombosis (CT). The authors will describe factors associated with CT risk including cancer type and stage at the time of diagnosis, race and ethnicity, and cancer-directed therapy. In addition, recurrent thrombosis and the effect of thromboembolism on survival in cancer patients will also be addressed.

C0358 Understanding recurrent thrombosis of antiphospholipid syndrome

2012 ◽  
Vol 130 ◽  
pp. S163
Author(s):  
Harberth Fernandez ◽  
Nuria Bermejo Vega ◽  
Carolina Martin Aguilera ◽  
Fernando Carnicero ◽  
Fatima Ibañez Espacio ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Recurrent Thrombosis

scholarly journals Antiphospholipid syndrome and recurrent thrombosis in children

2006 ◽  
Vol 55 (6) ◽  
pp. 850-855 ◽  
Author(s):  
Y. Berkun ◽  
S. Padeh ◽  
J. Barash ◽  
Y. Uziel ◽  
L. Harel ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Recurrent Thrombosis

Antiphospholipid syndrome

Hematology ◽  
2013 ◽  
Vol 2013 (1) ◽  
pp. 675-680 ◽  
Author(s):  
Wendy Lim
Keyword(s):  
Antiphospholipid Syndrome ◽  
Arterial Thrombosis ◽  
Rapid Development ◽  
Multiorgan Failure ◽  
Severe Form ◽  
Anticardiolipin Antibodies ◽  
Recurrent Thrombosis ◽  
Thrombotic Risk ◽  
Pregnancy Morbidity ◽  
Increased Risk

Abstract The antiphospholipid syndrome (APS) is defined by venous or arterial thrombosis and/or pregnancy morbidity in patients with persistent presence of antiphospholipid antibodies (aPLs). Catastrophic APS is the most severe form of APS, which is associated with rapid development of microvascular thrombosis resulting in multiorgan failure in patients with aPLs. Patients with APS and catastrophic APS are recognized to have a high risk of recurrent thrombosis that can occur despite anticoagulant therapy. Although antithrombotic therapy remains the mainstay of treatment, bleeding manifestations can complicate management and contribute to increased morbidity. Patients with persistently elevated aPL levels, particularly those who exhibit positive testing for lupus anticoagulant, anticardiolipin antibodies, and anti-β2GPI antibodies (triple positivity), appear to be at increased risk for thrombosis and pregnancy complications, whereas isolated positivity for aPLs appears to be associated with low risk. Recognizing that patients with APS have different thrombotic risk profiles may assist clinicians in assessing the risks and benefits of anticoagulation. The optimal type, intensity, and duration of anticoagulation in the treatment of APS remain controversial, particularly for arterial thrombosis and recurrent thrombosis. Future studies that delineate thrombotic risk in APS and evaluate current and novel anticoagulants as well as nonanticoagulant therapies are required.

Sign in / Sign up

Export Citation Format

Share Document